Efficacy of Danshen Class Injection in the Treatment of Acute Cerebral Infarction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Table 1

Results of the network meta-analysis of clinical effectiveness rate (lower left quarter) and neurological impairment (upper right quarter).

A	-0.37; (-2.82, 2.04)	-1.16; (-2.39, 0.07)	-4.38; (-5.07, -3.70)	-4.52; (-5.65, -3.4)	-5.01; (-7.19, -2.84)	-3.45; (-4.96, -1.96)	-2.56; (-5.40, 0.30)	-
1.64; (1.09, 2.55)	B	-0.79; (-3.41, 1.84)	-4.01; (-6.40, -1.60)	-4.15; (-6.70, -1.60)	-4.64; (-7.89, -1.38)	-3.08; (-5.94, -0.22)	-2.19; (-5.92, 1.56)	-
1.40; (1.11, 1.74)	0.89; (0.54, 1.35)	C	-3.22; (-4.40, -2.04)	-3.37; (-4.78, -1.93)	-3.86; (-6.4, -1.36)	-2.29; (-4.22, -0.35)	-1.41; (-4.51, 1.70)	-
4.03; (3.41, 4.69)	2.56; (1.65, 3.70)	2.90; (2.31, 3.59)	D	-0.14; (-1.38, 1.11)	-0.63; (-2.91, 1.67)	0.93; (-0.70, 2.57)	1.82; (-1.11, 4.74)	-
3.61; (2.80, 4.61)	2.30; (1.40, 3.46)	2.60; (1.95, 3.48)	0.90; (0.69, 1.17)	E	-0.49; (-2.96, 1.97)	1.07; (-0.80, 2.96)	1.96; (-1.10, 5.01)	-
4.15; (2.84, 5.87)	2.65; (1.44, 4.31)	3.00; (1.93, 4.43)	1.04; (0.68, 1.53)	1.17; (0.73, 1.81)	F	1.56; (-1.07, 4.21)	2.45; (-1.15, 6.04)	-
3.15; (2.35, 4.23)	2.02; (1.12, 3.19)	2.28; (1.55, 3.29)	0.79; (0.56, 1.10)	0.89; (0.58, 1.29)	0.79; (0.48, 1.22)	G	0.89; (-2.31, 4.13)	-
5.52; (1.37, 17.00)	3.54; (0.80, 11.3)	4.00; (0.96, 12.74)	1.38; (0.31, 4.46)	1.56; (0.37, 4.82)	1.38; (0.31, 4.46)	1.79; (0.42, 5.61)	H	-
922.30; (2.05, 424.80)	672.30; (1.27, 271.20)	668.30; (1.52, 296.00)	228.10; (0.52, 107.60)	272.00; (0.57, 119.70)	234.10; (0.49, 103.90)	312.20; (0.64, 132.8)	300.80; (0.32, 128.70)	I

A: WM; B: Danshen injection + WM; C: Fufang Danshen injection + WM; D: Danhong injection + WM; E: Danshenchuanxiongqin injection + WM; F: Sodium Tanshinone IIA Sulfonate injection + WM; G: Salvianolate injection + WM; H: Danshen Salvianolic Acids injection + WM; I: Guanxinning injection + WM. The result underlined meant it had statistical significant.